NY-CITCO-GROUP-OF-COMP
30.5.2019 18:05:10 CEST | Business Wire | Press release
The Citco Group of Companies, (“Citco”), a leading provider of asset servicing solutions to the global alternative investment industry, today announced a product partnership with S3 Partners, a leading fintech innovator and data analytics firm, and the integration of its BLACKLIGHT Treasury Management solution.
S3 Partners’ real-time, independent financing data prices opaque borrow and loan markets and redefines short interest, crowding and previously stale indicators for which the industry has had no centralized source. BLACKLIGHT leverages these analytics along with leading technology for better outcomes in investment process, risk management, and counterparty relationships.
The agreement between Citco and S3 allows Citco clients to get the benefit of BLACKLIGHT’s Financing Trade Cost Analytics (FinTCA) tools to maximize trade, margin and collateral exposures and efficiencies. The platform will be rolled out via Citco’s Æxeo Treasury platform.
“Our focus at Citco has always been to provide our clients with the best technologies and services to make their lives easier. This is why we have decided to integrate S3’s market-standard BLACKLIGHT suite of data and technology,” said Albert Bauer, Managing Director at Citco Fund Services (USA) Inc. “Integrating BLACKLIGHT into our existing Citco framework enables us to provide S3’s efficient insights to best execution, cost of margin and working capital and to monitor liquidity alongside our new Æxeo Treasury platform. Our clients have asked for these nuanced analytics which we can now offer via BLACKLIGHT with single-sign-on access and virtually no operational friction.”
“We are thrilled that Citco has chosen to partner with us and recognizes the value of our broker-neutral solutions,” said Bob Sloan, Founder of S3 Partners. “The Citco-S3 alliance, along with our distribution via Bloomberg, Nasdaq and Reuters, expands the reach of our technology and data to every player type and client segment.”
About Citco Group of Companies
The Citco Group of Companies (Citco) is a leading provider of asset servicing solutions to the global alternative investment industry. With over $1 trillion in assets under administration and 6,500 staff deployed across 40 countries, Citco’s unique culture of innovation and client-driven solutions has provided Citco’s clients with a trusted partner for more than four decades. Having grown organically into one of the largest asset servicers in the industry, Citco’s Fund Services division offers a full suite of middle office and back office services including, treasury and loan handling, daily NAV calculations and investor services, corporate and legal services, regulatory and risk reporting as well as tax and financial reporting services. Investing heavily in innovation and technology whilst further developing its current suite of client friendly solutions, Citco will continue as a flagbearer for the asset servicing industry. For more information, go to www.Citco.com .
About S3 Partners
Founded in 2003, S3 Partners is a financial technology and data company. Clients use our technology and data for better outcomes in their investment process, risk management, counterparty relationships, and investor relations. Like any resource, the integrity and purity of data is defined by how it’s sourced, how and why it’s filtered, who can access it, and how it’s interpreted. Data is only potential until you find a way to refine it. Refining data potential into financial power is S3’s business. Our suite of tools arms you to not just access data but to wield it; cut through marketplace opacity and see with clarity where opportunity lies for your business, portfolio, and the entire market. S3’s comprehensive data integrity powers your market perception and business intelligence so you can act with agility, on your own terms. For more information about S3 Partners, please visit s3partners.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190530005653/en/
Contact:
For Citco New York Hannah Beard | +1 646 274 1421 London Aryna Kastavetskaya | +44 20 3040 0871 citco@peregrinecommunications.com For S3 Partners ASC Advisors Steve Bruce / Taylor Ingraham sbruce@ascadvisors.com / tingraham@ascadvisors.com 203-992-1230
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom